Neuroleptic Malignant Syndrome malady
Rare diseases, Neuronal diseases categories
Aliases & Descriptions for Neuroleptic Malignant Syndrome:
MalaCards categories: See all MalaCards categories (disease lists)
Global: Rare diseases
Anatomical: Neuronal diseases
Rare neurological diseases
Characteristics (Orphanet epidemiological data):51
neuroleptic malignant syndrome:
Prevalence: 1-5/10000 (Europe)
NIH Rare Diseases:45 Neuroleptic malignant syndrome is a rare neurological condition that is caused by an adverse reaction to neuroleptic (tranquilizer) or antipsychotic drugs. these drugs are commonly prescribed for the treatment of schizophrenia and other neurological, mental, or emotional disorders. affected people may experience high fever, muscle stiffness, sweating, unstable blood pressure, altered mental status, and autonomic dysfunction. in most cases, the condition develops within the first 2 weeks of treatment with the drug; however, it may develop any time during the therapy period. the exact underlying cause of neuroleptic malignant syndrome is unknown. in some cases, more than one family member can be affected which suggests there may be a genetic component. upon diagnosis of the condition, the neuroleptic or antipsychotic drug is generally discontinued under a physician's supervision. medications and/or other interventions may also be recommended to manage symptoms. last updated: 7/14/2015
MalaCards based summary: Neuroleptic Malignant Syndrome is related to myocardial infarction and serotonin syndrome. An important gene associated with Neuroleptic Malignant Syndrome is CYP2D6 (Cytochrome P450, Family 2, Subfamily D, Polypeptide 6). The drugs bromocriptine and 2-bromoergocryptine mesylate have been mentioned in the context of this disorder. Affiliated tissues include brain, liver and tongue, and related mouse phenotypes are muscle and homeostasis/metabolism.
NINDS:46 Neuroleptic malignant syndrome is a life-threatening, neurological disorder most often caused by an adverse reaction to neuroleptic or antipsychotic drugs. Symptoms include high fever, sweating, unstable blood pressure, stupor, muscular rigidity, and autonomic dysfunction. In most cases, the disorder develops within the first 2 weeks of treatment with the drug; however, the disorder may develop any time during the therapy period. The syndrome can also occur in people taking anti-Parkinsonism drugs known as dopaminergics if those drugs are discontinued abruptly.
Wikipedia:68 Neuroleptic malignant syndrome (NMS) is a life-threatening neurological disorder most often caused by an... more...
Drugs for Neuroleptic Malignant Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):(show all 38)
Interventional clinical trials:(show all 26)
Search NIH Clinical Center for Neuroleptic Malignant Syndrome
Inferred drug relations via UMLS65/NDF-RT43:
MalaCards organs/tissues related to Neuroleptic Malignant Syndrome:33
Brain, Liver, Tongue, Subthalamic nucleus, Lung, Breast
Articles related to Neuroleptic Malignant Syndrome:(show top 50) (show all 581)
Search GEO for disease gene expression data for Neuroleptic Malignant Syndrome.
28ICD10 via Orphanet
37MESH via Orphanet
50OMIM via Orphanet
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
66UMLS via Orphanet